Expanding stroke treatment in China

Israel’s D-Pharm has expanded its commercial agreement with China’s Wanbang Biopharmaceuticals Ltd. for D Pharm’s leading product, DP-b99 for the treatment of ischemic stroke.

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published.